Not surprisingly, improved antibody detection has brought new challenges to the HLA community. The challenge is how best to utilize this new information in a way that facilitates, not hinders, appropriate transplantation.
Recent findings
Although very sensitive, recent studies have shown that not all donor-specific HLA antibodies (DSA) identified by SPADS predict a positive crossmatch or correlate with poor outcome. The lack of an absolute correlation between DSA, crossmatching and outcome presents a serious dilemma for the transplant community. The
dilemma is compounded by variable testing procedures and RG-7112 nonstandardized test kits that contribute to inconsistencies among laboratories. In addition, new functional assays are beginning to be applied and may identify potentially deleterious antibodies. Finally, advances in immunosuppressive therapies have made it possible to transplant across a positive crossmatch further confounding data integration.
Summary
Strategies AZD0530 order for HLA antibody detection are now predicated on solid-phase testing methods. These methods are sensitive, specific and provide the clinician with a comprehensive assessment of a patient’s HLA antibody profile. This review will discuss the evolution of antibody testing and point out the pitfalls, problems and challenges these new technologies have engendered.”
“Heart transplantation is an option for children with complex congenital heart
disease and cardiomyopathies. A patient’s quality of life and long-term survival depend on successful management of the surgical complications and adverse side effects of immunosuppression. INCB028050 clinical trial The purpose of this review was to summarize the practical management of postoperative care in this patient population and to make recommendations for the future.”
“Background: Spinal muscular atrophy (SMA) is a neuromuscular disease resulting from mutations in the survival motor neuron 1 (SMN1) gene. Recent breakthroughs in preclinical research have highlighted several potential novel therapies for SMA, increasing the need for robust and sensitive clinical trial platforms for
evaluating their effectiveness in human patient cohorts. Given that most clinical trials for SMA are likely to involve young children, there is a need for validated molecular biomarkers to assist with monitoring disease progression and establishing the effectiveness of therapies being tested. Proteomics technologies have recently been highlighted as a potentially powerful tool for such biomarker discovery.
Methods: We utilized label-free proteomics to identify individual proteins in pathologically-affected skeletal muscle from SMA mice that report directly on disease status. Quantitative fluorescent western blotting was then used to assess whether protein biomarkers were robustly changed in muscle, skin and blood from another mouse model of SMA, as well as in a small cohort of human SMA patient muscle biopsies.